Elutia Announces First Patient Implant of EluPro, the World’s First Drug-Eluting Bio-Envelope for Pacemakers and Neurostimulators Page 1

SILVER SPRING, Md., Sept. 5, 2024 (GLOBE NEWSWIRE) — Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a pioneer in drug-eluting biomatrix products, today announced a milestone achievement with the first-ever patient implantation of EluPro, the world’s first antibiotic-eluting biologic envelope cleared by the U.S. Food and Drug Administration (FDA). The groundbreaking procedure was performed by John Catanzaro, MD, MBA, chief of the Division of Cardiology, director of Cardiology Services and program director of the Clinical Cardiac Electrophysiology Fellowship at East Carolina University Health Medical Center in Greenville, North Carolina.